IDYA

IDEAYA Biosciences, Inc.

IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA\'s approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality - which represents an emerging class of precision medicine targets.

IDEAYA Biosciences, Inc. (IDYA) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Value (C).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C
Factor Score 2.4 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
B-
Factor Score 3.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -7.9
EV / EBITDA -5.1
Rev Growth YoY -95.1%
Gross Margin 0.0%
Price Return 3M -10.8%
Price Return 12M 5.9%
Catalyst Signal 0.00
Market Cap $3.2B
TTM Revenue $36.5M
Price / Sales 86.6
ROE -38.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C (2.4) C+ (2.5) C+ (2.8) B- (3.1) C+ (2.6) C+ (2.7)
2026-11-05 C (2.5) C+ (2.5) C+ (2.6) B (3.2) C+ (2.7) C+ (2.7)
2026-10-29 B- (2.9) B+ (3.5) B- (2.9) B (3.2) C+ (2.7) B- (3.0)
2026-10-22 B- (2.9) B (3.5) B- (2.9) B (3.2) C+ (2.6) B- (3.0)
2026-10-15 B- (2.9) B+ (3.5) B- (2.9) B- (3.0) C+ (2.6) B- (3.0)
Page 1 of 6